



**RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1632**

**PATENT**  
Attorney Docket No. 218122  
DHHS Reference No. E-323-2000/0-US-01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Hwu et al.

Application No. 09/803,578

Filed: March 9, 2001

For: **ACTIVATED DUAL SPECIFICITY  
LYMPHOCYTES AND THEIR  
METHODS OF USE**

Art Unit: 1632

Examiner: Wilson, Michael C.

**DECLARATION UNDER 37 C.F.R. § 1.132 OF DR. PATRICK HWU**


1. I, Patrick Hwu, am a co-inventor of the subject matter disclosed and claimed in the above-identified patent application.

2. I have read Example 4 of U.S. Patent 5,830,755 (herein referred to as the '755 patent). I recognize the work presented in Example 4 as my own work. The cells listed in Table 8 and labeled as "24 JK" or "24 JK FBP" are syngeneic to the cells labeled "38 TIL NV," "38 TNP-TIL," or "38 MOv-γ." That is, the cells are not allogeneic to each other. In this regard, these cells do not express a T cell receptor reactive with an allogeneic cell.

In re Appln. of Hwu et al.  
Application No. 09/803,578

3. I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 1/9/05

  
\_\_\_\_\_  
Patrick Hwu, M.D.